title: Hope persists for mesothelioma advances despite setbacks.
authors.forename: Bryant
authors.initials: B
authors.lastname: Furlow
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D002173:Cancer Care Facilities; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D005260:Female; D005544:Forecasting; D065026:Hope; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000523:psychology / Q000601:surgery; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy* / Q000523:psychology / Q000601:surgery; D000086002:Mesothelioma, Malignant; D061214:Patient Safety / Q000706:statistics & numerical data; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000523:psychology / Q000601:surgery; D011013:Pneumonectomy / Q000379:methods*; D018570:Risk Assessment; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C000613593:durvalumab; C520704:tremelimumab